Factors | Group | PFS | OS | ||||
HR | 95% CI | p value | HR | 95% CI | p value | ||
Age | continuous | 1.003 | 0.937 - 1.075 | 0.923 | 0.882 | 0.777 - 1.002 | 0.053 |
ECOG-PS | 1.2 vs. 0 | 1.839 | 0.668 - 5.057 | 0.238 | 1.570 | 0.303 - 8.136 | 0.591 |
Baseline PSA (ng/dL) | continuous | 1.001 | 0.998 - 1.003 | 0.499 | 1.002 | 0.998 - 1.006 | 0.276 |
≥100 vs. <100 | 1.103 | 0.432 - 2.813 | 0.838 | 2.556 | 0.628 - 10.407 | 0.190 | |
Baseline ALP (IU/l) | ≥359 vs. <359 | 1.269 | 0.497 - 3.237 | 0.618 | 1.147 | 0.306 - 4.305 | 0.839 |
Baseline LDH (IU/l) | ≥229 vs. <229 | 1.689 | 0.647 - 4.412 | 0.285 | 1.161 | 0.286 - 4.714 | 0.835 |
Baseline hemoblobin (g/dl) | <11.1 vs. 11.1< | 1.566 | 0.608 - 4.028 | 0.353 | 2.227 | 0.526 - 9.436 | 0.277 |
Biopsy Gleason Score | ≤8 vs. >8 | 1.214 | 0.389 - 3.790 | 0.738 | 1.261 | 0.313 - 5.082 | 0.744 |
Visceral metastasis | Yes vs. No | 2.276 | 0.773 - 6.704 | 0.136 | 6.139 | 1.229 - 30.671 | 0.027* |
PSA ≥ 50% decline in previous DP | No vs. Yes | 1.637 | 0.563 - 4.763 | 0.365 | 3.743 | 0.455 - 30.800 | 0.220 |
Total cycles of previous DP | ≤6 vs. >6 | 1.283 | 0.476 - 3.455 | 0.622 | 1.062 | 0.253 - 4.460 | 0.935 |
Duration from CRPC to DEC (month) | ≤12 vs. >12 | 3.055 | 1.015 - 9.202 | 0.047* | 5.790 | 1.148 - 29.215 | 0.033* |